Risk management in the treatment of type 2 diabetes with pioglitazone

Giuseppe Derosa, S. A T Salvadeo

Research output: Contribution to journalArticlepeer-review


Introduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality. Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes. Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention. Place in therapy: The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.

Original languageEnglish
Pages (from-to)51-60
Number of pages10
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publication statusPublished - 2009


  • Cardiovascular prevention
  • Diabetes mellitus
  • Glycated hemoglobin
  • Pioglitazone

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology


Dive into the research topics of 'Risk management in the treatment of type 2 diabetes with pioglitazone'. Together they form a unique fingerprint.

Cite this